Learning Objectives:  Chablani

1. Review current first-line treatment options for metastatic urothelial cancer

2. Provide an overview of how antibody drug conjugates work and benefits/shortcomings

3.  Discuss the phase II study that led to the FDA approval of Enfortumab Vedotin in Dec 2019 for metastatic urothelial cancer


Learning Objectives:  Hawking 

1.  To learn about the history of the medical futility debate.

2.  To develop a framework for thinking through futile cases and approaching families


Session date: 
06/29/2020 - 12:00pm to 1:00pm CDT
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Priyanka Chablani, MD & Michael Hawking, MD, MSc